Cargando…

Genome-wide Expression Analysis Identifies the Association between SEC14L2 and Castration-resistant Prostate Cancer Survival

Background: Mechanism of castration-resistant prostate cancer (CRPC) is still unclear. Our objective is to investigate the association between genes expression and CRPC through the genome-wide approach and functional researches. Methods: Differentially expressed genes (DEGs) between PCa and CRPC tis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Shiyun, Huang, Da, Huang, Jingyi, Yan, Jiaqi, Chen, Tianhe, Zhang, Ning, Jiang, Guangliang, Gao, Yi, Xu, Danfeng, Na, Rong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2021
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7974876/ https://www.ncbi.nlm.nih.gov/pubmed/33758595 http://dx.doi.org/10.7150/jca.50299

Ejemplares similares

Comprehensive subgroup analyses of survival outcomes between clear cell renal cell adenocarcinoma and papillary renal cell adenocarcinoma
por: Huang, Jingyi, et al.
Publicado: (2020)

Socioeconomic determinants are associated with the utilization and outcomes of active surveillance or watchful waiting in favorable‐risk prostate cancer
por: Huang, Da, et al.
Publicado: (2023)

Genome‐Wide 3′‐UTR Single Nucleotide Polymorphism Association Study Identifies Significant Prostate Cancer Risk‐Associated Functional Loci at 8p21.2 in Chinese Population
por: Zhang, Ning, et al.
Publicado: (2022)

The Sec14-like phosphatidylinositol transfer proteins Sec14l3/SEC14L2 act as GTPase proteins to mediate Wnt/Ca(2+) signaling
por: Gong, Bo, et al.
Publicado: (2017)

The Combined Effect of Polygenic Risk Score and Prostate Health Index in Chinese Men Undergoing Prostate Biopsy
por: Ruan, Xiaohao, et al.
Publicado: (2023)

Genetic polymorphisms at 19q13.33 are associated with [−2]proPSA (p2PSA) levels and provide additional predictive value to prostate health index for prostate cancer
por: Huang, Da, et al.
Publicado: (2021)

The heterogeneity and clonal evolution analysis of the advanced prostate cancer with castration resistance
por: Liu, Ao, et al.
Publicado: (2023)

Treatment-Emergent Co-Morbidities and Survival in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone or Enzalutamide
por: Lin, Yi-Ting, et al.
Publicado: (2021)

High-Resolution Genetics Identifies the Lipid Transfer Protein Sec14p as Target for Antifungal Ergolines
por: Filipuzzi, Ireos, et al.
Publicado: (2016)

Cost-Effectiveness Analysis of Prostate Health Index in Decision Making for Initial Prostate Biopsy
por: Huang, Da, et al.
Publicado: (2020)

Prostate-Specific Membrane Antigen Uptake and Survival in Metastatic Castration-Resistant Prostate Cancer
por: Vlachostergios, Panagiotis J., et al.
Publicado: (2021)

Family History of Cancers Increases Risk of Renal Cell Carcinoma in a Chinese Population
por: Xing, Siwei, et al.
Publicado: (2022)

Castration for Prostatic Hypertrophy
Publicado: (1899)

Upregulation of MAPK pathway is associated with survival in castrate-resistant prostate cancer
por: Mukherjee, R, et al.
Publicado: (2011)

Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer
por: Small, E J, et al.
Publicado: (2019)

(223)Ra-Dichloride in castration-resistant metastatic prostate cancer: improving outcomes and identifying predictors of survival in clinical practice
por: Dizdarevic, Sabina, et al.
Publicado: (2018)

Predicting castration-resistant prostate cancer after combined androgen blockade
por: He, Miao, et al.
Publicado: (2017)

Identification of marker genes and cell subtypes in castration-resistant prostate cancer cells
por: Lin, Xiao-Dan, et al.
Publicado: (2021)

secA, secD, secF, yajC, and yidC contribute to the adhesion regulation of Vibrio alginolyticus
por: Guo, Lina, et al.
Publicado: (2017)

Prostatic Neoplasia in the Intact and Castrated Dog: How Dangerous is Castration?
por: Schrank, Magdalena, et al.
Publicado: (2020)

Impact of Time to Castration Resistance on Cytoreductive Radiotherapy in Metastatic Castration-Resistant Prostate Cancer
por: Mai, Lixin, et al.
Publicado: (2020)

Molecular and cellular mechanisms of castration resistant prostate cancer
por: Huang, Yiqiao, et al.
Publicado: (2018)

Castration for Hypertrophy of the Prostate Gland
Publicado: (1895)

Time to castration resistance is a novel prognostic factor of cancer-specific survival in patients with nonmetastatic castration-resistant prostate cancer
por: Hakozaki, Yuji, et al.
Publicado: (2022)

Heterogeneous ensembles for predicting survival of metastatic, castrate-resistant prostate cancer patients
por: Pölsterl, Sebastian, et al.
Publicado: (2017)

Association of Body Composition With Survival and Treatment Efficacy in Castration-Resistant Prostate Cancer
por: Pak, Sahyun, et al.
Publicado: (2020)

Survival Outcomes by Race and Ethnicity in Veterans With Nonmetastatic Castration-Resistant Prostate Cancer
por: Rasmussen, Kelli M., et al.
Publicado: (2023)

Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer
por: George, Daniel J., et al.
Publicado: (2021)

Targeting Inflammatory Signaling in Prostate Cancer Castration Resistance
por: Zhong, Shangwei, et al.
Publicado: (2021)

Sec14-nodulin proteins and the patterning of phosphoinositide landmarks for developmental control of membrane morphogenesis
por: Ghosh, Ratna, et al.
Publicado: (2015)

Let’s talk about Secs: Sec61, Sec62 and Sec63 in signal transduction, oncology and personalized medicine
por: Linxweiler, Maximilian, et al.
Publicado: (2017)

The role of glutamine metabolism in castration-resistant prostate cancer
por: Zhao, Bing, et al.
Publicado: (2023)

Structure of the substrate-engaged SecA-SecY protein translocation machine
por: Ma, Chengying, et al.
Publicado: (2019)

Stepwise gating of the Sec61 protein-conducting channel by Sec63 and Sec62
por: Itskanov, Samuel, et al.
Publicado: (2021)

Survival outcomes and prognostic factors for first-line abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer
por: Tseng, Chi-Shin, et al.
Publicado: (2023)

Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate
por: Tagawa, Scott T., et al.
Publicado: (2021)

Role of SEC14-like phosphatidylinositol transfer proteins in membrane identity and dynamics
por: Montag, Karolin, et al.
Publicado: (2023)

Predicting survival time for metastatic castration resistant prostate cancer: An iterative imputation approach
por: Deng, Detian, et al.
Publicado: (2016)

Overall survival prediction in metastatic castration-resistant prostate cancer treated with radium-223
por: Vidal, Monica, et al.
Publicado: (2020)

A predictive model of overall survival in patients with metastatic castration-resistant prostate cancer
por: Mahmoudian, Mehrad, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_q9dpod1ma0b2ebtc0jtg0g0kq8